Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hypersensitivity, Immediate D006969 14 associated lipids
Stomatitis D013280 14 associated lipids
Angina, Unstable D000789 14 associated lipids
Hemorrhage D006470 15 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Neutropenia D009503 15 associated lipids
Encephalitis D004660 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Blister D001768 16 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Malabsorption Syndromes D008286 16 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Bronchial Spasm D001986 18 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Emilsson A and Sundler R Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and ionophore A23187. 1984 J. Biol. Chem. pmid:6321496
Mueller HW et al. 1-O-alkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1984 J. Lipid Res. pmid:6427378
Kramp W et al. Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. 1984 Chem. Phys. Lipids pmid:6744496
Hamasaki Y et al. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. 1984 Am. Rev. Respir. Dis. pmid:6547031
Wasserman SI The human lung mast cell. 1984 Environ. Health Perspect. pmid:6428878
Handley DA et al. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. 1984 Immunopharmacology pmid:6083990
Camussi G et al. Effect of platelet activating factor on guinea-pig papillary muscle. 1984 Experientia pmid:6086382
Blank ML et al. Conversion of 1-alkyl-2-acetyl-sn-glycerols to platelet activating factor and related phospholipids by rabbit platelets. 1984 Biochem. Biophys. Res. Commun. pmid:6497876
Lichey J et al. Pressure effects and uptake of platelet-activating factor in isolated rat lung. 1984 J Appl Physiol Respir Environ Exerc Physiol pmid:6501025
Buxton DB et al. Stimulation of glycogenolysis and platelet-activating factor production by heat-aggregated immunoglobulin G in the perfused rat liver. 1984 J. Biol. Chem. pmid:6501277
White GC Effect of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine on calcium fluxes by human platelet microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6428395
Mueller HW et al. The molecular species distribution of platelet-activating factor synthesized by rabbit and human neutrophils. 1984 J. Biol. Chem. pmid:6501307
Goldenberg MM and Meurer RD A pharmacologic analysis of the action of platelet-activating factor in the induction of hindpaw edema in the rat. 1984 Prostaglandins pmid:6505225
Wissner A et al. Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain. 1984 J. Med. Chem. pmid:6471071
Mallet AI et al. Rapid isocratic high-performance liquid chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. 1984 J. Chromatogr. pmid:6480761
Kenzora JL et al. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. 1984 J. Clin. Invest. pmid:6480824
Jackson EM et al. High performance liquid chromatography of platelet-activating factors. 1984 J. Lipid Res. pmid:6481248
Smith RJ et al. Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. 1984 Biochem. Pharmacol. pmid:6324816
Dewar A et al. Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig. 1984 J. Pathol. pmid:6481526
Buxton DB et al. Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine. 1984 J. Biol. Chem. pmid:6693418
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Pinckard RN et al. Molecular heterogeneity of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes. 1984 Biochem. Biophys. Res. Commun. pmid:6743335
Levi R et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. 1984 Circ. Res. pmid:6692502
Humphrey DM et al. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. 1984 Lab. Invest. pmid:6694349
Masugi F et al. Effect of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the rat. 1984 Life Sci. pmid:6694519
McGivern DV and Basran GS Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in man. 1984 Eur. J. Pharmacol. pmid:6592097
Beaubien BB et al. Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. 1984 Biochem. Biophys. Res. Commun. pmid:6594998
Archer CB et al. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. 1984 Prostaglandins pmid:6203139
Camussi G et al. Platelet-activating factor-induced loss of glomerular anionic charges. 1984 Kidney Int. pmid:6374251
Schlondorff D et al. Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. 1984 J. Clin. Invest. pmid:6423667
Vargaftig BB et al. [Platelet aggregation and PAF-acether. Pharmacologic interference]. 1984 J Pharmacol pmid:6374298
Ito S et al. Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. 1984 Lab. Invest. pmid:6379289
Bult H et al. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. 1984 Agents Actions Suppl. pmid:6382974
Hechtman HB et al. Role of humoral mediators in adult respiratory distress syndrome. 1984 Chest pmid:6383742
Kelton JG et al. The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. 1984 Ann. Intern. Med. pmid:6333196
Bussolino F et al. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. 1984 Exp. Hematol. pmid:6333353
Wodzinowska B and Krajewski T [Role of blood platelets and their membrane in the process of hemostasis]. 1984 Jan-Feb Postepy Hig Med Dosw pmid:6093087
Vemulapalli S et al. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. 1984 Jul-Aug Hypertension pmid:6378787
Cox CP et al. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). 1984 Mar-Apr Peptides pmid:6206481
Matsumoto M and Miwa M Platelet-activating factor-binding protein in human serum. 1985 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:3004155
Barnes JL and Venkatachalam MA The role of platelets and polycationic mediators in glomerular vascular injury. 1985 Semin. Nephrol. pmid:2957770
Leid RW and Potter KA Inflammation and mediators of lung injury. 1985 Vet. Clin. North Am. Food Anim. Pract. pmid:3907779
Shukla SD Platelet activating factor-stimulated formation of inositol triphosphate in platelets and its regulation by various agents including Ca2+, indomethacin, CV-3988, and forskolin. 1985 Arch. Biochem. Biophys. pmid:3875314
Roubin R and Benveniste J Formation of prostaglandins, leukotrienes and paf-acether by macrophages. 1985 Comp. Immunol. Microbiol. Infect. Dis. pmid:3910339
Wasserman SI Mast cell mediators in the blood of patients with asthma. 1985 Chest pmid:3880526
Halonen M et al. Participation of platelets in the physiologic alterations of the AGEPC response and of IgE anaphylaxis in the rabbit. Effects of PGI2 inhibition of platelet function. 1985 Am. Rev. Respir. Dis. pmid:3881060
Sybertz EJ et al. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. 1985 J. Pharmacol. Exp. Ther. pmid:3917504
Harlan JM Leukocyte-endothelial interactions. 1985 Blood pmid:3918593
Malone B et al. Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product. 1985 J. Biol. Chem. pmid:3918041
Proll MA et al. Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni. 1985 Mol. Pharmacol. pmid:2997592
MacIntyre DE et al. Endogenous and pharmacological mechanisms for the regulation of human platelet cytosolic free Ca2+. 1985 Nouv Rev Fr Hematol pmid:2997706
Lachachi H et al. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. 1985 Biochem. Biophys. Res. Commun. pmid:2998370
Hwang SB et al. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. 1985 J. Biol. Chem. pmid:2999126
Camussi G et al. The role of platelet-activating factor in experimental immune complex pathology. 1985 Int J Tissue React pmid:2932406
Brain SD and Williams TJ Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. 1985 Br. J. Pharmacol. pmid:2416378
Weber N and Benning H Ether glycerolipids: novel substrates for studying specificity of enzymes involved in glycerolipid biosynthesis in higher plants. 1985 Eur. J. Biochem. pmid:3967662
O'Neill C Partial characterization of the embryo-derived platelet-activating factor in mice. 1985 J. Reprod. Fertil. pmid:4067921
Mallet AI and Cunningham FM Structural identification of platelet activating factor in psoriatic scale. 1985 Biochem. Biophys. Res. Commun. pmid:3970690
Valone FH Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). 1985 Biochem. Biophys. Res. Commun. pmid:3970703
Camussi G and Brentjens JR Inhalation of horseradish peroxidase by rabbits with specific IgE antibodies results in release into the circulation of platelet-activating factor and in lung lesions. 1985 Clin. Immunol. Immunopathol. pmid:3971603
Chesney CM et al. Desensitization of human platelets by platelet activating factor. 1985 Biochem. Biophys. Res. Commun. pmid:3977920
Nakayama R et al. Generation of acetyl glyceryl ether phosphorylcholine from the rat skin and muscle tissues stimulated by moxibustion. 1985 Biochem. Biophys. Res. Commun. pmid:3977939
Archer CB et al. Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. 1985 Br. J. Dermatol. pmid:3978036
Gerdin B et al. Permeability-increasing ability of PAF-acether in rat skin. 1985 Inflammation pmid:3980073
Ardaillou N et al. Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. 1985 Am. J. Physiol. pmid:3918460
Pritchard PH et al. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). 1985 Blood pmid:4063532
Wissner A et al. Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group. 1985 J. Med. Chem. pmid:4032438
Wimberly HC et al. Functional and biochemical characterization of immunologically derived equine platelet-activating factor. 1985 Vet. Pathol. pmid:4035942
MacIntyre DE et al. Tumour-promoting phorbol esters inhibit agonist-induced phosphatidate formation and Ca2+ flux in human platelets. 1985 FEBS Lett. pmid:2981715
Ludwig JC et al. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. 1985 Arch. Biochem. Biophys. pmid:4037794
Surles JR et al. Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain. 1985 J. Med. Chem. pmid:4038418
Aul C et al. [Thrombotic thrombocytopenic purpura]. 1985 Klin. Wochenschr. pmid:4038757
Hanahan DJ et al. A novel approach to structure proof of glyceryl ether-containing glycerophospholipids. Base-catalyzed methanolysis of platelet-activating factor (AGEPC) at 60 degrees C. 1985 J. Lipid Res. pmid:4067422
Atkins JN Platelet-aggregating factor in thrombotic thrombocytopenic purpura. 1985 Ann. Intern. Med. pmid:4038861
Klöcking HP et al. Release of tissue-type plasminogen activator by platelet-activating factor. 1985 Thromb. Res. pmid:4040278
Pedersen AK and FitzGerald GA Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. 1985 Clin. Pharmacol. Ther. pmid:3917387
Sugiura T et al. Transacylation of 1-O-alkyl-SN-glycero-3-phosphocholine (lyso platelet-activating factor) and 1-O-alkenyl-SN-glycero-3-phosphoethanolamine with docosahexaenoic acid (22:6 omega 3). 1985 Biochem. Biophys. Res. Commun. pmid:2935146
Oda M et al. Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. 1985 J. Immunol. pmid:3917470
Bergelson LD et al. Influence of platelet activation factor and prostaglandins on cholesterol esterification in human plasma. 1985 FEBS Lett. pmid:4043408
Kilpatrick JM and Virella G Inhibition of platelet-activating factor by rabbit C-reactive protein. 1985 Clin. Immunol. Immunopathol. pmid:4042435
Monnens L et al. Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood. 1985 Clin. Nephrol. pmid:4042442
Pirotzky E et al. Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. 1985 Agents Actions pmid:4003192
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Sugiura T and Waku K CoA-independent transfer of arachidonic acid from 1,2-diacyl-sn-glycero-3-phosphocholine to 1-O-alkyl-sn-glycero-3-phosphocholine (lyso platelet-activating factor) by macrophage microsomes. 1985 Biochem. Biophys. Res. Commun. pmid:3919727
O'Flaherty JT Neutrophil degranulation: evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor, and 5-HETE. 1985 J. Cell. Physiol. pmid:2981891
Khan SN et al. Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins. 1985 Eur. J. Pharmacol. pmid:3920056
Wasserman SI The mast cell and theophylline in asthma. 1985 Am. J. Med. pmid:3002176
Bushfield M et al. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. 1985 Biochem. J. pmid:3002327
Grandel KE et al. Association of platelet-activating factor with primary acquired cold urticaria. 1985 N. Engl. J. Med. pmid:2410790
Bussolino F et al. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. 1985 J. Immunol. pmid:2411812
Johnson HM and Torres BA Mechanism of calcium ionophore A23187-induced priming of bone marrow-derived macrophages for tumor cell killing: relationship to priming by interferon. 1985 Proc. Natl. Acad. Sci. U.S.A. pmid:2412225
Fjellner B and Hägermark O Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. 1985 Acta Derm. Venereol. pmid:2416164
Shen TY et al. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. 1985 Proc. Natl. Acad. Sci. U.S.A. pmid:2983307
Avdonin PV and Altukhova IP [Blocking with phorbol ester, a protein kinase C activator, of receptor-dependent platelet calcium channels]. 1985 Biokhimiia pmid:2416359
Pannocchia A and Hardisty RM Cyclic AMP inhibits platelet activation independently of its effect on cytosolic free calcium. 1985 Biochem. Biophys. Res. Commun. pmid:2983714
Avdonin PV et al. [Mechanism of increase in Ca2+ level in platelet cytoplasm induced by aggregating factors]. 1985 Biokhimiia pmid:3000463
Lee TD et al. Heterogeneity in mast cell populations. 1985 Clin Immunol Rev pmid:2417770
Nishihira J et al. Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. 1985 Tohoku J. Exp. Med. pmid:3001971